Business
Respiri (ASX:RSH) share price on watch following FDA approval
The Respiri Ltd (ASX: RSH) share price is on watch today after the company advised it has received United States Food and Drug Administration (FDA) clearance for its Wheezo app.
About Respiri
Respiri is a software-as-a-service (SaaS) company supporting asthma patients to monitor and manage their asthma. The company views that asthma is often under-diagnosed and under-treated, creating a substantial burden to sufferers and their families.
Respiri has created an eHealth SaaS platform, ‘Wheezo’, that uses a device and app to measure, record and monitor asthma symptoms. The device records breath sounds over 30 seconds to be analysed in…
-
Noosa News14 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General9 hours agoFarmers develop ‘autofill’ tech so agricultural robots can operate around the clock
-
General11 hours agoChoosing an online exercise program can be confusing. Here’s what to look out for
-
Noosa News14 hours agoNowhere is growing like this corner of Queensland. It’s changing the political game